SciELO - Scientific Electronic Library Online

 
vol.46 issue2Increase of care service at the National Institute of Oncology and Radiobiology from 1992 to 2000Frequency, risk factors and effect of the main clinical causes of graft dysfunction in the first month of renal transplant on survival author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Cubana de Medicina

Print version ISSN 0034-7523On-line version ISSN 1561-302X

Abstract

ESTEVEZ DEL TORO, Miguel H. et al. Predictive factors of response to cyclophosphamide-based induction therapy for proliferative lupus nephritis. Rev cubana med [online]. 2007, vol.46, n.2. ISSN 0034-7523.

Renal damage brings significant additional morbidity and mortality to patients with systemic erythematous lupus (SEL). Thirty eight patients with SEL and proliferative lupus nephritis were studied to determine what percentage of them has good response to intravenous cyclophosphamide-based induction therapy and the factors that allow predicting that response. These subjects were seen in the period from January 1997 to December 2006 and received induction therapy based on 6 doses of cyclophosphamide pulses every month. A longitudinal prognostic evaluation study was undertaken. Response to induction therapy was seen in 27 patients (71.1%) that was complete in 24 cases and partial in 3 patients. The analyzed variables comprising socio-demographic, clinical and histological ones, already existing before the treatment, were not significantly associated to response prediction including renal function test and renal activity, and histological chronicity indexes. It was concluded that cyclophosphamide is effective in induction therapy for proliferative lupus nephritis; however, the predictive factors for cases that will not respond to it remained unknown.

Keywords : Systemic erythematosus lupus; lupus nephritis; cyclophosphamide; induction therapy; response to treatment.

        · abstract in Spanish     · text in Spanish

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License